ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1940

Timely Initiation of Steroid Sparing Therapy in Uveitis Patients – a Quality Improvement Initiative

Bibi Ayesha1, Claudia Castiblanco2, Clement Tagoe3, Sarah Baron2 and Sharon Rikin2, 1Montefiore Medical Center, Metuchen, NJ, 2Montefiore Medical Center, Bronx, NY, 3Montefiore Medical Center, New York

Meeting: ACR Convergence 2024

Keywords: Access to care, autoimmune diseases, Intervention, Quality Indicators, quality of care

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 18, 2024

Title: Health Services Research – ACR/ARP Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose:  

Uveitis is the inflammation of the eye, which is third leading cause of preventable blindness in the United States. Corticosteroids are the first line of management to suppress inflammatory response. Patients with recurrent uveitis have structural complications that need prolonged course of steroids, resulting in iatrogenic complications. These are the patients who will need long term steroid sparing immunosuppressive therapy. A collaborative Rheumatology-Ophthalmology team approach could improve management of uveitis patients requiring prolonged immunosuppressive therapy. Our aim was to increase the percentage of uveitis patients, at risk of vision loss who are evaluated by the rheumatology team for initiation of steroid sparing therapy, these are patients with uveitis on topical steroid therapy for more than 6 months or oral steroid therapy for more than 2 months or patients with structural complications.

Methods: After the IRB approval, electronic medical records were queried (January 2017 – December 2023), to assess the baseline data we identified 2684 patients with uveitis, 41 experienced blindness and 501 patients had a referral to rheumatology. Of the 501 patients only 204 (41%) had a rheumatology appointment scheduled appointment (Figure 1). We queried the physicians, secretaries, patient scheduling staff and uveitis patients, to identify the barriers for timely scheduling rheumatology appointments. We utilized Quality Improvement (QI) tool, process map to outline the current uveitis patient scheduling practice at the Rheumatology clinic. To assess the progress of the QI intervention, we had uveitis patients who received referral documentation as the process measure and number of uveitis patients scheduled for the rheumatology appointment as the outcome measure.

Results: We utilized prioritization matrix to plan the interventions (Figure 2). As the first intervention, plan-do-study-act (PDSA-1) cycle, we identified the ophthalmologist who treat uveitis patients and discussed with them to place referral electronic medical record (EMR) epic order and simultaneously email the rheumatologist, that increased the number of rheumatology referrals to 114 (Figure 3).  To accommodate these increased referrals in the rheumatology clinic, we adapted clustering clinic model as PDSA cycle 2 by identifying the rheumatologist who treat uveitis patients with steroid sparing therapy and schedule the uveitis patients on a particular day week, to avoid over booking and streamline the clinic workflow.

Conclusion: We identified potential barriers to, uveitis patients getting timely rheumatology appointments. Our QI improvement results demonstrated that a collaborative Rheumatology-Ophthalmology team approach could improve timely scheduling rheumatology appointments for uveitis patients who require steroid sparing therapy. This initiative can be replicated on a larger scale to improve clinical care in patients requiring steroid sparing therapy.

Supporting image 1

Figure 1: Baseline Data Uveitis Patients with Rheumatology Referrals

Supporting image 2

Figure 2 : Prioritization Matrix

Supporting image 3

Figure 3 : Post Quality Improvement (QI) Intervention


Disclosures: B. Ayesha: None; C. Castiblanco: None; C. Tagoe: None; S. Baron: None; S. Rikin: None.

To cite this abstract in AMA style:

Ayesha B, Castiblanco C, Tagoe C, Baron S, Rikin S. Timely Initiation of Steroid Sparing Therapy in Uveitis Patients – a Quality Improvement Initiative [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/timely-initiation-of-steroid-sparing-therapy-in-uveitis-patients-a-quality-improvement-initiative/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/timely-initiation-of-steroid-sparing-therapy-in-uveitis-patients-a-quality-improvement-initiative/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology